The Claim
In non-obese adults with type 2 diabetes, a reduction in epicardial fat volume after 12 weeks of ipragliflozin treatment is significantly correlated with changes in body weight and BMI, but not with changes in visceral fat area or skeletal muscle mass.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In non-obese adults with type 2 diabetes, a decrease in fat around the heart after 12 weeks of ipragliflozin use is linked to changes in overall body weight and BMI, but not to changes in abdominal fat or muscle mass.
See the scientific wording
In non-obese adults with type 2 diabetes, the reduction in epicardial fat volume following 12 weeks of ipragliflozin is significantly correlated with changes in body weight and BMI, but not with changes in visceral fat area or skeletal muscle mass, suggesting distinct fat depot regulation.
Blocking glucose reabsorption in the kidneys causes the body to lose sugar in urine, which lowers blood sugar and insulin levels. With less insulin, fat cells around the heart stop storing fat and start burning fat for energy, leading to a reduction in heart fat without affecting belly fat or muscle mass.
What the research says
1 studyIn people with type 2 diabetes who aren’t overweight, taking a drug called ipragliflozin reduced the fat around the heart, and this reduction was linked to losing overall body weight and having a lower BMI — but not to losing belly fat or gaining muscle. The study confirms this exact pattern.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.